Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC’s Copenhagen Facility Seattle, April 30, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership...